Healthcare stocks declined on Wall Street today, down 2.5%. More broadly, the Dow Jones Industrial Average declined 1.1%, the Nasdaq was down 1.0% and the S&P 500 declined 1.1%. Some of the biggest losers among healthcare stocks include …
Investor Place · 7/25/2015
Healthcare Stocks
Investors in Clovis Oncology Inc (Symbol: CLVS) saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS
NASDAQ · 7/21/2015
Here are some of the leading gainers and losers in the healthcare sector today: Repligen Corp (RGEN)- The company’s stocks retreated 4.5 pct. Incyte Corp (INCY)- The company’s stocks lost 4.1 pct. Immunogen …
Fx Pips · 7/27/2015
More from Bing News
Clovis Oncology (NASDAQ:CLVS) was upgraded by research analysts at Goldman Sachs from a “buy” rating to a “conviction-buy” rating in a report released on Monday, reports. The firm currently has a $110.00 price target on … · 7/21/2015
Likewise, almost 22% of the equity's float is sold short, representing two weeks of pent-up buying demand, at CLVS' average trading volumes. For other stocks in analysts' crosshairs, read Analyst Upgrades: Amazon.
Schaeffer's Investment Research · 7/20/2015
The disclosure for this sale can be found here. Clovis Oncology (NASDAQ:CLVS) traded down 0.35% during mid-day trading on Friday, hitting $87.06. 570,226 shares of the company’s stock traded hands. Clovis Oncology has a one year low of $35.33 and …
Ticker Report · 7/17/2015
... rating and six have given a buy rating to the company’s stock. Clovis Oncology presently has a consensus rating of Buy and a consensus price target of $104.63. Clovis Oncology (NASDAQ:CLVS) opened at 87.06 on Friday. Clovis Oncology has a 52 …
Mideast Times · 7/19/2015
Stocks were marginally higher on Monday morning on a day where ... Clovis Oncology Inc. (NASDAQ: CLVS) was reiterated as Buy at Goldman Sachs, but the firm added it to the prized Conviction Buy List with a $110 …
24/7 Wall ST · 7/20/2015
Analyst Upgrades
Threatening that is Clovis Oncology's (NASDAQ:CLVS) Rucaparib. Rucaparib has recently finished ... should be enough to make investors take a second look at AstraZeneca stock. Based on these factors, it is my opinion that AstraZeneca is a definite hold ...
Seeking Alpha · 7/27/2015
NEW YORK (TheStreet) -- Clovis Oncology (CLVS) shares are up 13.7% to $87.90 in market trading on Monday after analysts at Goldman Sachs (GS) nearly doubled the company's price target to $117 from $68 before the opening bell today. The upgraded …
The Street · 4/13/2015